Shattuck Labs Inc (STTK)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$5.49-1.96%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Shattuck Labs Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	88,889
EPS	—	-0.114
Annual ending 2026-12-31
Revenue	—	95,455
EPS	—	-0.485
Annual ending 2027-12-31
Revenue	—	100,227
EPS	—	-0.518

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
maintain sufficient cash through financing	The company maintains cash flow through recent $75M stock offering.	Intact	no successful capital raises of at least $75M within next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
reduce net losses per share	A primary condition in Shattuck Labs Inc's published investment case. The stated target is EPS loss improves to less than -$0.40 per share next 12 months.	Broken	EPS loss worsens beyond -$0.50 per share next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
sustain or improve revenue trajectory	A primary condition in Shattuck Labs Inc's published investment case. The stated target is revenue decline less than 10% next 12 months.	Broken	revenue decline exceeds 10% next 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.52

$-0.52 → $-0.52 · observed estimates

FY2027 revenue$0.00B

$0.02B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.52	$19,300,000	6 / 6
2026-07-25	$-0.52	$19,300,000	6 / 6
2026-07-26	$-0.50	$19,300,000	6 / 6
2026-07-27	$-0.50	$19,300,000	6 / 6
2026-07-28	$-0.50	$19,300,000	6 / 6
2026-07-29	$-0.50	$19,300,000	7 / 8
2026-07-30	$-0.50	$19,300,000	7 / 8
2026-07-31	$-0.50	$19,300,000	7 / 8
2026-08-01	$-0.50	$19,300,000	7 / 8
2026-08-02	$-0.50	$0	9 / 8
2026-08-03	$-0.50	$0	9 / 8
2026-08-04	$-0.50	$19,300,000	7 / 8
2026-08-05	$-0.50	$19,300,000	7 / 8
2026-08-06	$-0.50	$0	9 / 8
2026-08-08	$-0.50	$19,300,000	7 / 8
2026-08-09	$-0.50	$0	9 / 8
2026-08-10	$-0.50	$19,300,000	7 / 8
2026-08-12	$-0.50	$19,300,000	7 / 8
2026-08-13	$-0.50	$19,300,000	7 / 8
2026-08-14	$-0.50	$19,300,000	7 / 8
2026-08-15	$-0.50	$19,300,000	7 / 8
2026-08-16	$-0.50	$19,300,000	7 / 8
2026-08-17	$-0.50	$19,300,000	7 / 8
2026-08-18	$-0.50	$19,300,000	7 / 8
2026-08-19	$-0.50	$19,300,000	7 / 8
2026-08-20	$-0.52	$19,300,000	7 / 8
2026-08-21	$-0.52	$19,300,000	7 / 8
2026-08-22	$-0.52	$19,300,000	7 / 8
2026-08-23	$-0.52	$19,300,000	7 / 8
2026-08-24	$-0.52	$19,300,000	7 / 8
2026-08-25	$-0.53	$110,000	7 / 8
2026-08-26	$-0.53	$110,000	7 / 9
2026-08-27	$-0.53	$110,000	7 / 9
2026-08-28	$-0.53	$110,250	8 / 6
2026-08-29	$-0.53	$110,250	8 / 6
2026-08-30	$-0.53	$110,250	8 / 6
2026-08-31	$-0.53	$110,250	8 / 6
2026-09-01	$-0.53	$110,250	8 / 6
2026-09-02	$-0.53	$110,250	8 / 6
2026-09-03	$-0.53	$110,250	8 / 6
2026-09-04	$-0.53	$110,250	8 / 6
2026-09-05	$-0.53	$110,250	8 / 6
2026-09-06	$-0.53	$110,250	8 / 6
2026-09-07	$-0.53	$110,250	8 / 6
2026-09-08	$-0.53	$110,250	8 / 6
2026-09-09	$-0.53	$110,250	8 / 6
2026-09-10	$-0.53	$110,250	8 / 6
2026-09-11	$-0.53	$110,250	8 / 6
2026-09-12	$-0.53	$110,250	8 / 6
2026-09-13	$-0.53	$110,250	8 / 6
2026-09-14	$-0.53	$110,250	8 / 6
2026-09-15	$-0.53	$110,250	8 / 6
2026-09-16	$-0.53	$110,250	8 / 6
2026-09-17	$-0.53	$110,250	8 / 6
2026-09-18	$-0.53	$110,250	8 / 6
2026-09-19	$-0.53	$110,250	8 / 6
2026-09-20	$-0.53	$110,250	8 / 6
2026-09-21	$-0.53	$110,250	8 / 6
2026-09-22	$-0.53	$110,250	8 / 6
2026-09-23	$-0.53	$110,250	8 / 6
2026-09-24	$-0.53	$110,250	8 / 6
2026-09-25	$-0.53	$110,250	8 / 6
2026-09-26	$-0.53	$110,250	8 / 6
2026-09-27	$-0.53	$110,250	8 / 6
2026-09-28	$-0.53	$110,250	8 / 6
2026-09-29	$-0.53	$110,250	8 / 6
2026-09-30	$-0.53	$110,250	8 / 6
2026-10-01	$-0.53	$110,250	8 / 6
2026-10-02	$-0.53	$110,250	8 / 6
2026-10-03	$-0.53	$110,250	8 / 6
2026-10-04	$-0.53	$110,250	8 / 6
2026-10-05	$-0.53	$110,250	8 / 6
2026-10-06	$-0.53	$110,250	8 / 6
2026-10-07	$-0.53	$110,250	8 / 6
2026-10-08	$-0.53	$110,250	8 / 6
2026-10-09	$-0.53	$110,250	8 / 6
2026-10-10	$-0.53	$110,250	8 / 6
2026-10-11	$-0.53	$110,250	8 / 6
2026-10-12	$-0.53	$110,250	8 / 6
2026-10-13	$-0.53	$110,250	8 / 6
2026-10-14	$-0.52	$100,227	9 / 6
2026-10-15	$-0.52	$100,227	9 / 6
2026-10-16	$-0.52	$100,227	9 / 6
2026-10-17	$-0.52	$100,227	9 / 6
2026-10-18	$-0.52	$100,227	9 / 6
2026-10-19	$-0.52	$100,227	9 / 6
2026-10-20	$-0.52	$100,227	9 / 6
2026-10-21	$-0.52	$100,227	9 / 6
2026-10-22	$-0.52	$100,227	9 / 6
2026-10-23	$-0.52	$100,227	9 / 6
2026-10-24	$-0.52	$100,227	9 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	8	1
2026-07-01	10	0
2026-08-01	11	0
2026-09-01	11	0
2026-10-01	12	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 11

$17.00New observation · no comparable prior

WedbushOct 2 · prior May 8

$11.00 → $14.00+27.3%

NeedhamOct 2

$19.00New observation · no comparable prior

$0$10.45$20.90

1 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

maintain sufficient cash through financingDirect metric needs a verified mapping
reduce net losses per sharePublished status: Broken
sustain or improve revenue trajectoryPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-50.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Shattuck Labs Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not a proven earnings compounder. The long-term thesis is in a watch state: management is advancing its programs and reports funding into 2029, but the business remains loss-making and recent performance trails its industry cohort.

What's priced into Shattuck Labs Inc

STTK trades at a 10.85% premium to peers, with the valuation model pointing to program optionality, or potential value from future drug development, as the main driver. Model confidence is low, and the priced-in tag is unjustified, so the available evidence does not support a clear view that the premium matches the business outlook.

What the fundamentals likely do

Near-term results remain uncertain: a recent earnings beat and an earlier in-line report are balanced by weak performance, a 41% estimated miss probability, and a high-miss-rate industry where peers have missed lately. Management has kept SL-325's Phase 2b trial on track and SL-846's planned Phase 1 timeline unchanged, while cash and short-term investments rose to $213.3 million by 2026-Q2 after offerings and warrant exercises; management projects funding into 2029.

What Shattuck Labs Inc hinges on

The multi-year thesis depends on progress in the Crohn's disease trial and the planned SL-846 development timeline, alongside preserving the stated cash runway. Near-term risks include a guidance cut and worsening jobs data; sector momentum could help if healthcare bellwethers continue to report strong results and raise guidance.